We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+9.39%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.45B
AUM Growth
-$251M
Cap. Flow
-$193M
Cap. Flow %
-7.88%
Top 10 Hldgs %
50.47%
Holding
123
New
19
Increased
24
Reduced
18
Closed
19

Top Buys

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$65.2M
2
GOSS icon
Gossamer Bio
GOSS
+$34.6M
3
XLRN
Acceleron Pharma
XLRN
+$26.3M
4
EPZM
Epizyme, Inc
EPZM
+$19.6M
5
BPMC
Blueprint Medicines
BPMC
+$18.5M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$10.4M
2
BLUE
bluebird bio
BLUE
+$10.2M
3
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$10M
4
ANAB icon
AnaptysBio
ANAB
+$9.57M
5
ARGX icon
argenx
ARGX
+$8.23M

Sector Composition

Rank Sector Weight
1 Healthcare 63.96%
2 Consumer Discretionary 16.48%
3 Technology 3.08%
4 Real Estate 0.36%
5 Communication Services 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRYS icon
51
Krystal Biotech
KRYS
$10.7B
$9.87M 0.4%
300,000
+25,000
+9% +$589K
RGNX icon
52
Regenxbio
RGNX
$617M
$9.74M 0.4%
170,000
– –
WVE icon
53
Wave Life Sciences
WVE
$1.12B
$9.71M 0.4%
+250,000
New +$10.1M
XLRN
54
CALL
DELISTED
Acceleron Pharma
XLRN
$9.31M 0.38%
200,000
– –
DNLI icon
55
Denali Therapeutics
DNLI
$3.8B
$9.29M 0.38%
400,000
-100,000
-20% -$2.09M
REPL icon
56
Replimune Group
REPL
$442M
$9.13M 0.37%
600,000
+150,000
+33% +$1.87M
NIO icon
57
CALL
NIO
NIO
$12B
$8.93M 0.36%
1,750,000
+750,000
+75% +$5.32M
VICI icon
58
VICI Properties
VICI
$29.8B
$8.75M 0.36%
400,000
– –
TCDA
59
DELISTED
Tricida, Inc. Common Stock
TCDA
$8.69M 0.35%
225,000
+100,000
+80% +$2.33M
TCRR
60
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$8.54M 0.35%
+490,000
New +$8.69M
AGEN
61
Agenus
AGEN
$274M
$8.17M 0.33%
140,113
– –
CBAY
62
DELISTED
Cymabay Therapeutics
CBAY
$7.97M 0.33%
600,000
+100,000
+20% +$1.06M
SPRO icon
63
Spero Therapeutics
SPRO
$68.9M
$7.69M 0.31%
600,000
– –
RCKT icon
64
Rocket Pharmaceuticals
RCKT
$336M
$7.02M 0.29%
400,000
– –
ALDR
65
DELISTED
Alder Biopharmaceuticals
ALDR
$6.83M 0.28%
500,000
+300,000
+150% +$3.89M
FOLD
66
CALL
DELISTED
Amicus Therapeutics
FOLD
$6.8M 0.28%
500,000
– –
TGTX icon
67
TG Therapeutics
TGTX
$8.28B
$6.43M 0.26%
800,000
+400,000
+100% +$2.16M
HTHT icon
68
Huazhu Hotels Group
HTHT
$13.4B
$6.32M 0.26%
+150,000
New +$5.13M
TBIO
69
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$6.11M 0.25%
600,000
– –
APLS
70
DELISTED
Apellis Pharmaceuticals
APLS
$5.85M 0.24%
+300,000
New +$4.72M
ICPT
71
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$5.59M 0.23%
+50,000
New +$5.46M
CRSP icon
72
CRISPR Therapeutics
CRSP
$4.66B
$5.18M 0.21%
145,000
– –
STML
73
DELISTED
Stemline Therapeutics, Inc.
STML
$5.14M 0.21%
400,000
– –
ACIU icon
74
AC Immune
ACIU
$231M
$5.05M 0.21%
1,000,000
+250,000
+33% +$1.59M
SWAV
75
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$5.02M 0.21%
+150,000
New +$4.98M
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2019 Portfolio in Review

As of Q1 2019, Artal Group held 123 positions worth $2.45B, down 9.3% from $2.7B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Artal Group withdrew a net $193M in Q1 2019, closing 19 positions and reducing 18 holdings. Its most notable exit was Clementia Pharmaceuticals Inc., an estimated $10M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, up from 49% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Artal Group opened a new position in NVIDIA worth $75.4M.

  • Artal Group's largest Q1 2019 buy was NVIDIA: 16,800,000 shares worth $75.4M.
  • Artal Group added most to Acceleron Pharma in Q1 2019, an estimated $26.3M increase.
  • Artal Group's biggest Q1 2019 reduction was Array Biopharma Inc, cutting an estimated $10.4M.
  • Artal Group fully exited Clementia Pharmaceuticals Inc. in Q1 2019, selling an estimated $10M.
  • Artal Group's ten largest holdings make up 50% of its $2.45B portfolio in Q1 2019.
  • Artal Group opened 19 new positions and closed 19 in Q1 2019.
  • Artal Group's portfolio value fell 9.3% quarter-over-quarter to $2.45B.

Based on Artal Group's 13F filing for Q1 2019, filed 10 May 2019.